Physician profile
Ching-Long C Ni
NPI 1518038595
$734,115.84
in general payments reported to CMS, 2019-2025
3 companies · $971 in 2025
The $971 reported for 2025 was more than what 79% of Body Imaging providers received nationally (typical 2025 total: $84.96).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198K · 2020: $319K · 2021: $204K · 2024: $13K · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $14,202.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $318,563.46 | 2020 | |
| Medtronic, INC. | $217,770.76 | 2021-2025 | Inpen Smart Insulin Delivery System |
| Medtronic USA, INC. | $197,781.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ching-Long Ni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.